Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.

摘要: Background The treatment of schizophrenia is challenging due to the wide range symptoms (positive, negative, cognitive) associated with disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) a common occurrence. Atypical targeting 5-HT2A and more at cognitive negative compared typical antipsychotics, these drugs also result such as metabolic syndromes. Objective To identify evidence literature elucidates pharmacological profile aripiprazole.s. Methods We searched PubMed for peer reviewed articles on aripiprazole its clinical efficacy, side-effects, pharmacology, effects animal models symptoms. Results Aripiprazole newer atypical antipsychotic displays unique profile, including partial agonism functionally selective properties. has potential treat least well other antipsychotics. drug favorable side-effect low propensity EPS or Animal have been used determine efficacy symptom management. In instances, resulted reversal deficits extinction, pre-pulse inhibition, social withdrawal. Because requires greater than 90% occupancy rate be clinically active does not produce EPS, this suggests effect intracellular signaling pathways. Conclusion A combination factors dopamine system stabilization via agonism, functional selectivity receptors, serotonin-dopamine interaction may contribute ability successfully manage This review examines mechanisms action further clarify actions aripiprazole.